VYNE Therapeutics Announces Positive Phase Ib Efficacy Data for FMX114 from Phase Ib/IIa Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis

VYNE Therapeutics Inc. announced positive efficacy results from the Phase Ib segment of a Phase Ib/IIa clinical trial evaluating FMX114 for the treatment of mild-to-moderate atopic dermatitis.